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Background: The burden of acute gastroenteritis on children and their families continues to be enormous.
Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent
a rapidly expanding field. Although clinical trials in children with gastroenteritis have been performed, most have
significant flaws, and guidelines do not consistently endorse their use.
Methods/Design: PROGUT is a randomized, placebo-controlled, double-blind, five-center, Canadian, emergency
department trial. Children aged 3 months to 48 months who present between November 2013 and June 2017 with
<72 hours of gastroenteritis symptoms will be assessed for eligibility. A total of 886 children will be randomized
(1:1 allocation via an internet based, third party, randomization service) to receive 5 days of a combination probiotic
agent (Lactobacillus rhamnosus and L. helveticus) or placebo. All participants, caregivers, and outcome assessors will
be blinded to group assignment. The study includes three key outcomes: 1) clinical - the development of moderate
to severe disease following an emergency department (ED) evaluation that employs a validated clinical score
(Modified Vesikari Scale); 2) safety - side effect; and 3) mechanism - fecal secretory immunoglobulin A levels.
Discussion: Definitive data are lacking to guide the clinical use of probiotics in children with acute gastroenteritis.
Hence, probiotics are rarely prescribed by North American physicians. However, the following current trends
obligate an urgent assessment: 1) probiotics are sold as food supplements, and manufacturers can encourage their
use while their relevance has yet to be established; 2) North American and European government agencies remain
concerned about their value and safety; 3) some institutions are now recommending the routine use of probiotics;
and 4) parents of affected children are often providing probiotics. With probiotic consumption increasing in the
absence of solid evidence, there is a need to conduct this definitive trial to overcome the limitations of prior work
in this field.
Trial registration: ClinicalTrials.gov: NCT01853124; first registered 9 May 2013.
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In the United States each year, there are approximately
179 million episodes of acute gastroenteritis (AGE) [1,2].
Children often suffer from prolonged [3] and severe illness;
among hospitalized children, 19% have clinical sepsis, 7%
seizures, and 4% require intensive care unit admission [4].
Apart from supportive care, healthcare providers have little
to offer to relieve suffering [5].
Probiotics, which are viable microbial preparations
that have a beneficial effect on the health of the host, [6]
represent a rapidly expanding field. Meta-analyses on their
use in children with AGE [7-11] are encouraging; however,
they question the relevance of the outcomes evaluated
[7,11,12] and advocate for large randomized clinical trials
(RCT) [13] in ambulatory pediatric populations [7].
Consequently, in North America, probiotics are rarely
used [14-19]. However, current trends obligate an urgent
assessment for several reasons. First, probiotics are sold as
food supplements, and manufacturers encourage their use
through campaigns, making health claims that are not be
supported by rigorous research [20-23]. At stake is the
$33 billion/year worldwide probiotic market, which is
growing at 13% annually [24]. Second, government agencies
remain concerned about the value and safety of probiotics
[25-27]. Third, some institutions are recommending the
routine use of probiotics [28]. Finally, parents are often pro-
viding probiotics [16], and consumption is increasing in the
absence of evidence.
Prior research suffers from the following shortcomings:
1. Outcome measures used to date have limited clinical
meaning. That is, studies have focused on individual
symptoms, without consideration of the full picture
of the illness [29]. Thus, the significance of the
conclusions is questioned [12,30].
2. Quality of studies is inadequate. Most are small,
single-center studies [11] that have been conducted
by pharmaceutical companies [7]. Many negative
studies remain unpublished [31]. Design issues are a
concern; only 16% of studies adequately reported the
four key methodological assessment parameters [11].
3. Inadequate data are available from research in the
relevant patient population. Though 95% or more of
children are treated as outpatients [32], only a
handful of small studies have focused on outpatients
[12]. Hospitalized children are more likely to benefit
from probiotics [9,11,33]. Only a single ED study
has been performed. In this study, 129 children
received a probiotic or placebo agent, and the
authors found statistically insignificant trends
towards a reduction in stool frequency and duration
among those administered a probiotic [34].
4. Knowledge about the in vivo mechanism of action in
AGE is limited [35,36].In light of the above considerations, we have obtained
funding from the Canadian Institutes for Health Research
(CIHR) to conduct the PROGUT (Probiotic Regimen
for Outpatient Gastroenteritis Utility of Treatment) trial
employing a combination product, Lacidofil™, which con-




In children aged 3 to 48 months of age who present with
less than 72 hours of AGE-like symptoms to an ED, the
administration of a probiotic agent when compared with
a placebo:
1. will result in a significantly lower proportion of
children developing moderate to severe disease over
the subsequent 2 weeks.
2. will not be associated with a significantly greater
occurrence of minor side effects.




Clinical efficacy will be determined as follows:
1. For previously healthy children, ages 3 to
48 months, who present with less than 72 hours of
AGE-like symptoms to an ED, is the probability of
developing moderate to severe disease (Modified
Vesikari Scale (MVS) score ≥9) following ED
evaluation, significantly different in those who receive
Lacidofil compared to those who receive placebo?
2. Is there a difference in the (a) mean duration of
diarrhea or (b) mean duration of vomiting?
3. Is there a difference in the probability of requiring
an unscheduled healthcare provider visit?
Side effect profile
In this group of patients, is the proportion that experiences
a side effect (for example, bloating, fever, abdominal disten-
tion, or rash) significantly different in those who receive
Lacidofil compared to placebo?
Mechanism of action
In this group of patients, are fecal sIgA levels 5 days and
4 weeks after the initiation of treatment higher in those
who receive Lacidofil compared to those who receive
placebo?
Study design
This a randomized, placebo-controlled, double-blind,
five-center, ED-based trial. A total of 886 children will
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colony forming units (CFU)/day] or placebo.
Ethics approval
Site-specific approval has been granted by the local ethics
committees at the following study sites: University of
Calgary, The Hospital for Sick Children (HSC), Children’s
Hospital of Eastern Ontario, Centre Hospitalier Universi-
taire Ste-Justine, and the IWK Health Centre. A Notice of
Authorization has been granted by Health Canada’s Health
Product and Food Branch, Biologics and Genetic Therapies
Directorate (file #: 9427 - U0206 - 77C).
Study population
The diagnosis of gastroenteritis is at the discretion of
the ED supervising physician and symptoms may or
may not include vomiting. Alternative terminologies
that reflect as similar diagnosis are acceptable (for ex-
ample, viral illness, diarrhea, vomiting, upper respiratory
infection, post-infectious gastroenteritis, antibiotic associ-
ated diarrhea, toddler’s diarrhea, viral infection, enteritis,
viremia, fever, and bronchiolitis).
Inclusion criteria
All of the following must be met for inclusion:
1. ≥ 3 watery stools in a 24-hour period [37]
2. duration of vomiting or diarrhea <72 hours
3. age 3 to <48 months
Exclusion criteria
Exclusion criteria include:
1. presence of an indwelling vascular access line or
structural heart disease [38].
2. taking immunosuppressive therapy, or known
history of immunodeficiency [39].
3. hematochezia in the preceding 72 hours, underlying
significant chronic gastrointestinal problem or
inflammatory bowel disease. This does not including
constipation, gastroesophageal reflux or chronic
pain.
4. family member with an indwelling vascular access
line, on immunosuppressive therapy, or with a
known immunodeficiency. This does not include use
of short course oral or inhaled steroids.
5. bilious vomiting.
6. supplemental probiotic use in the preceding
2 weeks. The consumption of foods containing
probiotics will not result in exclusion.
7. previously enrolled in this trial.
8. daily communication will not be possible while
symptomatic.
9. allergy to soy.10. pre-existing, or known, pancreatic dysfunction or
insufficiency [40].
11. oral or gastrointestinal surgery within the preceding
7 days.
Intervention
Informed consent will be obtained from each participant’s
legally authorized guardian prior to enrollment into the
study. Once consent is provided, the first dose will be
administered in the ED. The sachet’s contents will be
sprinkled into 30 mL of oral rehydration solution (ORS).
Caregivers will receive instructions on study drug admin-
istration, completion of study forms, what and how much
fluid to drink, criteria for seeing a health care practitioner
or returning to the ED [see Additional file 1] and stan-
dardized AGE discharge instructions.
All patients will take one sachet every 12 hours for
5 days, at meal time, even once symptoms have resolved.
The dose will be repeated once should vomiting occur
within 15 minutes of medication administration. Children
who are hospitalized will continue as per study protocol.
Investigational agents
We have obtained independent analyses to confirm the
viable CFU count and microbe identity [see Additional
files 2 and 3]. Lacidofil data indicate that a dose of 3 to
6 × 109 CFU/day is effective [41]. A recent pilot trial,
which employed low (4 × 109 CFU/day) and high (8 ×
109 CFU/day) dose arms, found no side effects with either
dose. However, a positive association is postulated to exist
between the probiotic dose and clinical benefits [7], with
most positive studies employing doses ≥6 × 109 CFU/day
[9]. Thus, a dose of 8 × 109 CFU/day is being employed
for the current study. The duration of therapy has been
selected based on the best available evidence, the recom-
mendations of experts in the field, previous studies, and
the typical duration of most episodes of AGE [42].
Stool sample testing
Stool samples from all participants will be tested for
bacteria and viruses. For children who do not provide a
stool specimen prior to discharge, rectal swabs will be
performed. For patients enrolled at HSC and Alberta
Children’s Hospital (ACH), additional stool samples will
be collected on Days 5 and 28 for sIgA testing.
Randomization
Sequence generation
We used www.randomize.net to produce the study
randomization lists stratified by site. The lists were
sent to the central pharmacy at ACH where an independ-
ent research pharmacist prepared consecutively numbered
kits according to the randomization schedule. The kits
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ment containers and temperature monitors.
Allocation concealment
The site www.randomize.net uses industry standard se-
curity to send data over the internet. Randomization
employed random blocks of 4 and 6 with a 1:1 allocation
ratio.
Implementation
A log of all screened patients is being maintained. If con-
sent is obtained, study staff collects baseline demographic
clinical variables and complete the data collection forms.
Study staff then log into www.randomize.net to randomize
the patient.
Bias
The probiotic and placebo powders are identical in ap-
pearance, taste, texture and smell. Participants, families,
healthcare providers, data collectors, outcome adjudica-
tors, and data analysts are blinded. Co-interventions
and other sources of confounding are being recorded.
The trial has been registered at www.clinicaltrials.gov
(NCT01853124).
Concomitant medications
The concomitant administration of antibiotics is permit-
ted as probiotics remain effective when given concomi-
tantly with antibiotics [43]. Their use is at the discretion
of the child’s treating physician. Similarly, antipyretics,
anti-emetics, and other medications may be administered.
ORS will be provided during the ED visit. Discharge in-
structions will be provided.
Outcomes
Primary outcome (clinical)
The primary outcome is the development of moderate
to severe disease in the 2 weeks after the index ED visit
as measured by the MVS (Table 1) [44]. The original 20
point Vesikari Score, which has been employed as a dichot-
omous variable in many clinical studies [45-53], correlates
with other meaningful measures such as caregiver anxiety,Table 1 Modified Vesikari Scale
Points 0
Diarrhea duration 0
Maximum number of diarrheal stools/24-hour period 0
Vomiting duration (d) 0
Maximum number of vomiting episodes/24-hour period 0
Maximum recorded fever <37.0˚C R
Future healthcare visit 0%
Treatment None
R, rectal.helplessness, stress, [54] parental worry, behavioral changes,
and impact on the parents’ daily activities and distress [55].
However, percent dehydration, an element of the original
score, is challenging to quantify due to difficulties in collect-
ing follow-up weights, determining when rehydration has
occurred, and the variation related to timing of voiding,
stooling, eating, and drinking. Thus, this element is omitted
or incorrectly assigned in many studies. The modified score
includes an important and easy to obtain outcome that re-
flects global disease severity - need for unscheduled health-
care provider visits within 2 weeks of the index visit [44].
This is supported by evidence that the utilization of profes-
sional medical care correlates with disease severity [54].
Follow-up will occur daily until both the diarrhea and
vomiting have resolved. On Day 14 each variable is
assigned a score for the entire study period (Time 0 to
Day 14); each patient gets a single total score for the
study. Variables are scored based on the worst 24-hour
period or on the total duration of symptoms or are
based on the occurrence of an outcome.
Regardless of the score assigned at Time 0 (that is, the
pre-enrollment score), everyone reverts to a score of 0 at
enrollment. The pre-enrollment score will serve as a co-
variate in a secondary analysis of the primary outcome
and will be employed for subanalysis purposes. The pri-
mary outcome will only include symptoms and out-
comes that occur following the ED visit and will not be
directly impacted by the pre-enrollment score.
With the original score, severe disease was defined as ≥11
[45,46,51,52,56-58] and moderate as ≥9 [59]. In the deriv-
ation study, [44] construct validity was proven by using
scores of ≥9 to define moderate and ≥11 to define severe
disease. These cut-points were associated with significant
increases in other measures of disease severity (for example,
daycare (P = 0.01) and work absenteeism (P = 0.002)) [44].
Secondary outcomes
Clinical secondary outcomes are:
1. duration of diarrhea, which is time from treatment
initiation until the appearance of the last watery
stool [60-62].1 2 3
1 to 96 hours 97 to 120 hours ≥121 hours
1 to 3 4 to 5 ≥6
1 to 24 hours 25 to 48 hours ≥49 hours
1 2 to 4 ≥5
37.1 to 38.4˚C R 38.5 to 38.9˚C R ≥39.0˚C R
- Primary care Emergency department
Rehydration Hospitalization -
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children who vomit ≥3 times over the 24 hours
prior to the ED visit, and duration is defined as ‘time
from treatment initiation until last vomiting
episode’.
3. return visits for unscheduled care to a healthcare
provider related to vomiting, diarrhea, dehydration,
fever, or fluid refusal, within two weeks. Scheduled
visits will not be included.
4. work and daycare absenteeism.
Safety
To determine if short course probiotic administration to
young children with AGE is associated with an increase
in minor side effects, groups will be compared regarding
the development of any side effects with particular atten-
tion paid to bloating or abdominal distention (grouped for
analysis), duration of fever, and buttock rash.
Mechanism
To determine if probiotic administration increases fecal
sIgA levels in children with AGE, the first stool sample
produced following enrollment will be collected along
with samples on Days 5 and 28. We will determine if
fecal sIgA levels are greater among children treated with
a probiotic agent compared with placebo. Levels will be
correlated with clinical findings.
Data retrieval
1. Daily Telephone/Electronic Survey Communication:
At the index visit, caregivers will be asked their
preferred method of communication - electronic
versus telephone. Caregivers will be contacted daily
by the identified method until both the diarrhea and
vomiting have resolved. A standardized collection form
will be employed. Detailed questioning will follow
positive responses. Compliance will be assessed on
Day 5. To maximize validity, caregivers will be
reminded of the importance and method of
administering the probiotic/placebo.
2. Chart Review: We will verify data regarding revisits,
intravenous hydration, hospitalization, and
microbiology testing using each center’s medical
record database.
3. Database Reviews: Provincial databases and
Canadian Institute for Health Information databases
will be employed to verify future health care
provider use.
Health service research issues
An economic evaluation will be conducted alongside the
RCT. The incremental cost effectiveness will be deter-
mined by assessing resources and costs associated withthe treatment of AGE for children who receive the




The sample size estimate was based on the assessment of
the between-group difference in proportions of children
with a post-randomization score ≥9 on the MVS. The
adoption of probiotic use can be recommended if the pro-
portion of the primary outcome is significantly lower
among those who receive the probiotic medication. Calcu-
lations were based on a two-sided α of 0.05 and power of
0.90. The null hypothesis is H0: Pc - PI = 0, where PI and
PC are the outcome probabilities in the intervention and
control groups, respectively. The alternative hypothesis is
HA:│PI - PC│ >0.10. Ten content experts from the United
States and Canada were surveyed regarding the minimal
clinically important difference; absolute risk differences
ranging from 7.5 to 15% were suggested. A conservative
estimate of 10% was selected for the primary outcome.
Our estimate for the development of moderate to severe
AGE in the controls is based on data collected as part of
two evaluations of the MVS in nearly 750 children in U.S.
[63] and Canadian EDs. [44] Approximately 25% of eligible
children had scores consistent with moderate to severe dis-
ease. Employing a baseline probability of 25% in the con-
trols, the required sample size to compare proportions
between two groups is 670 [64]. Based on previous work by
our group [65-67], we assume a 10% loss to follow-up, 5%
drop out, and 2.5% drop in probabilities. Adjustment for
O’Brien-Fleming monitoring boundaries requires a further
2% increase. Thus, the final sample size required is 886.
Safety
RCTs employing probiotics have not attributed any
adverse events to probiotic administration [11]. Given our
sample size, a significant difference between groups will
be easily detected.
Mechanism
A study evaluating the impact of formula supplementation
with oligosaccharides found fecal sIgA values of 729 and
377 μg/g in the intervention and control groups, respect-
ively [68]. Assuming a clinically significant difference of
300 μg/g, a standard deviation of 500 μg/g, 80% power
and a type I error of 0.05, the required sample size is 45
subjects/group. We will recruit 100 patients to provide
multiple stool samples for this phase of the study.
Statistical analysis
All analyses will be undertaken by the intention-to-treat
principle. Adverse events will use the ‘as treated’ principle.
Patients who drop out or crossover will be followed and
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characteristics will be compared between groups using
frequency counts and percentages for discrete variables,
and means, medians, standard deviations, and interquartile
ranges for continuous variables. Sensitivity analyses will be
performed to assess the possibility and consequences of
losses to follow-up not occurring at random.
Clinical
The proportion of children with moderate to severe dis-
ease will be analyzed by utilizing a Mantel-Haenszel test,
stratified by clinical center. Significance for the primary
outcome measure will be determined using a two-sided
0.05 level. Secondary analyses of the primary outcome will
employ logistic regression methods to adjust for covariates
that may be imbalanced between groups. We will analyze
the MVS as a continuous variable through a stratified
Wilcoxon rank-sum test. The overall significance level
for statistical tests on the secondary outcomes will be
set at 0.05. Holm’s method will be used to adjust for
multiple comparisons. The continuous variables of dur-
ation of diarrhea and vomiting will be measured in hours
and analyzed with a Van Elteren test, stratified by clinical
center. Unscheduled healthcare visits will be analyzed
using a Mantel-Haenszel test, stratified by clinical center.
The tertiary outcomes of the number of days the child is
absent from daycare and the days the caregiver is absent
from work will be analyzed using an appropriate model
with robust estimates for standard errors. Dichotomous
outcomes to be evaluated but unlikely to achieve signifi-
cance include ED revisits, intravenous rehydration, and
hospitalization. Additional analyses involving these out-
comes will include linear and logistic regression models
that adjust for possible effects of baseline characteristics.
Safety
The proportions of children experiencing any side effect,
as reported by the caregivers, will be compared between
groups using the Mantel-Haenszel test, stratified by site.
The analysis will evaluate the presence/absence of side
effects, as an aggregate outcome variable.
Mechanism
To test for a difference in fecal secretory IgA the Wilcoxon
rank-sum test will be performed. As this is a mechanistic
outcome and the motivation of its study is distinct from
other outcomes, the test will be performed at the 0.05 level.
Data will be analyzed to determine if fecal secretory IgA
levels 5 days and 4 weeks after initiation of treatment are
higher among children treated with probiotic than those
treated with placebo. Fecal sIgA data will also be analyzed
by outcome, comparing levels among those with mild dis-
ease to those with moderate to severe disease.Planned subgroup analyses
1. The presence of a MVS ≥9 will be analyzed by (i)
age <1 year, (ii) breast-feeding status, (iii) antibiotic
usage and (iv) protocol compliance.
2. Duration of vomiting will be analyzed only in those
patients who have had ≥3 episodes of vomiting in
the 24 hours prior to enrollment.
3. Daycare and work absenteeism will only be analyzed
for children who attend daycare and caregivers who
work.
4. In children with rotavirus infection, an interaction
term will be added between treatment and rotavirus
positivity in a logistic regression model. The
independent variables in the model will be (i)
treatment group, (ii) rotavirus positivity (yes/no) and
(iii) the interaction between treatment group and
rotavirus positivity.
5. Fecal sIgA levels will be subanalyzed based on the
mother’s breast-feeding status.
Safety
The Data Safety Monitoring Committee (DSMC) will
meet after 200 and 500 patients to review enrollment,
study procedures, form completion, data quality, loss to
follow-up, drop-in rate, and interim safety and efficacy
results. The analyses will test the hypothesis that the
probability of developing moderate to severe AGE in the
probiotic arm is equal to that in the placebo arm. Conser-
vative O’Brien-Fleming monitoring boundaries, imple-
mented using the Lan-DeMets alpha-spending function
approach, will be used as guidelines for early stopping for
safety or efficacy. Based on trends and adverse events, the
DSMC may decide to meet sooner than planned using
boundaries adjusted accordingly. Because this trial in-
volves children under the age of 6 months, the DSMC has
approved a plan to complete an interim safety analysis on
the first 20 subjects enrolled under 6 months of age. All
serious adverse events will be reported within 24 hours to
the DSMC and based on these reports; the DSMC may
decide to conduct a safety analysis before the full 20
subjects have been enrolled in this age group. Other-
wise, a blinded analysis will be conducted after the 20
subjects <6 months of age have been enrolled. This data
will be unblinded if the DSMC deems it necessary to
conduct an unblinded interim safety analysis. The results
of this analysis will be communicated to Health Canada at
the discretion of the DSMC chair should any concerns be
identified. The DSMC consists of a biostatistician (Nick
Barrowman, PhD-Ottawa), and two physicians with RCT
expertise (Drs. Mark Roback-Minnesota and Terry Klassen
(Chair) -Winnipeg).
An adverse event has been defined as any unfavorable
or unintended clinical or other occurrence during the
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pation in the research study.
Expected adverse drug reactions/events include the
following, which were deemed to be part of the natural
history of the underlying disease process:
1. hospitalization
2. future healthcare provider visit, ED return visit
3. IV rehydration
4. abdominal pain, distension
5. vomiting, diarrhea, fever, flatulence
Because expected adverse events are part of the natural
history of AGE and diarrheal illness in children, they
will not need to be reported as adverse events. This infor-
mation will be recorded in normal study data collection
processes. Any serious adverse event (SAE) that occurs
after the first sachet administered will be reported to the
Research Ethics Board (REB) and the study subject will be
followed until the conclusion of the event. Any serious ad-
verse event to the natural health product will be reported
to Health Canada. An SAE has been defined as any of the
following:
1. results in death.
2. is life-threatening. This refers to an event in which
the patient was at immediate risk of death; it does
not refer to an event that might have caused death
had it been more severe.
3. results in a persistent or significant disability/
incapacity.
4. is medically significant. Important medical events
that may not result in death, be life-threatening, or
require hospitalization may be considered SAEs
when, based upon appropriate medical judgment,
may jeopardize the patient and may require medical
or surgical intervention to prevent one of the
outcomes listed in this definition.
Unblinding should only occur in the event that there is
clinical concern regarding the possibility of bacteremia/
septicemia or when it is felt by the treating physician that
unblinding would alter the clinical care being provided.
All patients whose therapy is intentionally unblinded will
discontinue the experimental therapy. Approval from the
principal investigator or designate will be obtained prior
to unblinding. If the principal investigator cannot be
reached, unblinding can be performed and the princi-
pal investigator informed within 24 hours via email or
telephone.
Subjects will be withdrawn from the study if:
1. after enrollment they are determined to meet any of
the exclusion criteria.2. the subject is admitted to an intensive care unit.
3. it is deemed by the treating physician that the child’s
health may be jeopardized by continued
participation in the study.
4. the patient’s caregivers wish to withdraw their child
for whatever reason.
Trial management
The Clinical Research Informatics Core (CRIC), based at
the University of Alberta, will act as a central repository
for all study data and they will be responsible for the
provision of data collection technology and clinical data
management services. Dr. Willan will supervise all data
analyses. Dr. Freedman takes overall responsibility for the
study. Double data entry will be employed on a random
sampling of subjects at various time points throughout the
study. The study has a Steering Committee that includes
senior clinical research team members (Drs. Gorelick,
Schuh, and Johnson), Dr. Sherman (gastroenterologist),
Dr. Kuppermann (past-Chair of PECARN), Dr. Dean
(Director of the Central Data Management and Coordinat-
ing Center for PECARN), and Dr. Plint (Chair of PERC).
Discussion
It should be noted that a similar study is also being con-
ducted in the United States with funding provided by the
National Institutes of Health (NCT01773967). The study
will be employing very similar study design; however, a
different probiotic agent (Lactobacillus GG) will serve
as the investigational agent. These parallel studies will
provide a unique opportunity to conduct meta-regression
analyses, and together they will provide a clear message
regarding the use of probiotic products in this study
population.
Trial status
As of 16 April 2014, 152 children have been enrolled at
the five study sites.
Additional files
Additional file 1: Discharge instruction list provided to study
participants (Canada).
Additional file 2: Lactobacilli enumeration.
Additional file 3: Identification of the bacterial population present
using randomly amplified polymorphic DNA technique.
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